Clinuvel Pharmaceuticals is a biotechnology business based in Australia. Clinuvel Pharmaceuticals shares (CUV) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Clinuvel Pharmaceuticals has a trailing 12-month revenue of around $81.8 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Clinuvel Pharmaceuticals, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $12.96 - $21.4707 |
|---|---|
| 50-day moving average | $14.619 |
| 200-day moving average | $16.2195 |
| Target price | $26.41 |
| PE ratio | 26.2982 |
| Dividend yield | $0.05 (0.33%) |
| Earnings per share (TTM) | $0.57 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$14.99
| 1 week (2024-04-18) | -1.96% |
|---|---|
| 1 month (2024-03-26) | 9.02% |
| 3 months (2024-01-25) | -4.22% |
| 6 months (2023-10-26) | -2.22% |
| 1 year (2023-04-26) | -25.31% |
|---|---|
| 2 years (2022-04-26) | -7.98% |
| 3 years (2021-04-26) | -50.98% |
| 5 years (2019-04-26) | -33.08% |
Valuing Clinuvel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinuvel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clinuvel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Clinuvel Pharmaceuticals shares trade at around 26x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Clinuvel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $44.4 million (£0.0 million).
The EBITDA is a measure of a Clinuvel Pharmaceuticals's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $81.8 million |
|---|---|
| Operating margin TTM | 42.37% |
| Gross profit TTM | $70.8 million |
| Return on assets TTM | 14.71% |
| Return on equity TTM | 18.98% |
| Profit margin | 36.88% |
| Book value | 3.606 |
| Market capitalisation | $751.4 million |
TTM: trailing 12 months
Dividend payout ratio: 8.73% of net profits
Recently Clinuvel Pharmaceuticals has paid out, on average, around 8.73% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinuvel Pharmaceuticals shareholders could enjoy a 0.33% return on their shares, in the form of dividend payments. In Clinuvel Pharmaceuticals's case, that would currently equate to about A$0.05 per share.
While Clinuvel Pharmaceuticals's payout ratio might seem low, this can signify that Clinuvel Pharmaceuticals is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 4 September 2023 (the "ex-dividend date").
Clinuvel Pharmaceuticals's shares were split on a 1:10 basis on 11 November 2010. So if you had owned 10 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Clinuvel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Clinuvel Pharmaceuticals shares which in turn could have impacted Clinuvel Pharmaceuticals's share price.
Over the last 12 months, Clinuvel Pharmaceuticals's shares have ranged in value from as little as $12.96 up to $21.4707. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Clinuvel Pharmaceuticals's is 0.744. This would suggest that Clinuvel Pharmaceuticals's shares are less volatile than average (for this exchange).
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
AMP Ltd Preferred
AUD104.71
ANZ Group Holdings Ltd. Pfd.
AUD101.63
ANZ Group Holdings Ltd. Pfd.
AUD102.92
Challenger Ltd Preferred
AUD105.63
Macquarie Group Ltd Pref C
AUD102.97
Macquarie Group Preferred
AUD103.13
Suncorp Group Ltd Pref
AUD100.79
Westpac Banking Corp Pref
AUD102.87
Everything we know about the Sun Silver IPO, plus information on how to buy in.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.